PAR 0.60 Osteoarthritis Co. MC $170m TRADEGATE:56M ish Cash at hand (31 July23) SOI 237m Potential head n shoulders Low volume spring in background (SOS) +ve phase 2 results/News in background Shouldnt take much to punch this dribble of supply in the neck, tick tockLongby nfury8113
$PAR lots of overhead supply. Needs to break that d/t line...Recent positive news but takes time to turn around a stale ship. See how they trade em. Plenty time to get set in this one. Longby Hodgo3
$PAR.AX #PAR $PAR Support zone $1.80Should grip and rip. Based on the technicals alone, it's come down to the support zone, where buyers and news catalysts should hold firm imo. by FoxesTrader0
ASX: PAR - A possible 3rd wave upI'm seeing a possible 3rd wave move up, it seems to of completed a larger ABC corrective structure with a 1-2 wave from the C low. I have set an early entry at 3.13, i want to see a sharp move up for evidence of a 3rd wave. If we do not get a sharp price move up the i will review this entry.by TradingWITSUpdated 0
PAR Currently at a strong support, needs to hold here tomorrow. If it does its likely to head to the neckline of an M formation. This may hold short term resistance before we continue higher to create a W formation. DYOR, only educational. As the environment changes charts will be posted.Longby camb0_1234
PARADIGM - 160% PROFIT TO CONTINUEPay close attention to PARADIGM (PAR). 3 Potential Moves 1. We bounce off the .382 Fib level and return to test the 2.80 mark which we saw on 11/05/20 -Being the end of the trading week I suspect the latter. 2. We break the .382 Fib level and Uptrend and head for the 'Golden Pocket' -Bounce off strong support at 2.00 mark -MACD is starting to squeeze but if we find momentum next week we could start to spread again. -PAR loves the .5 Fibonacci Retracement level. (Short term fact) -We hit the deeper uptrend and continue back up towards the 2.80 mark to test a strong EQ Resistance Level. Very Possible -It regains buyer momentum in the 'Golden Pocket' between the .5-.618 Fib Level. Very Possible -Positive news released early next week bring strong buying sentiment back into the market and create an Higher Low ready for the next leg up. 3. We BREAK both uptrend trendlines creating NEW Bearish Market Structure and head for the next Major Support @ 1.48 Another company im keeping a close eye on. PARADIGM BIOPHARMACEUTICALS LTD is a late stage drug development company with their aim to treat musculoskeletal disorders in humans with degenerative disease driven by injury, viral infection, aging or genetic predisposition. They have a cash balance sheet of $108 Million (06/04/20), FDA Approval, IP Protection & Patents, Agreements that stand for 20 years regarding manufacturing, Fully funded until 2022. EYES ON!!! These Ideas are NOT 'Financial Advice'!. Scenarios are based off a mixture of TA and Fundamentals current at the time. All IMO GLTAH. Happy Hunting!!!by Trader_JohnniUpdated 3312
PAR: Stoch Pattern Analysis30 day pattern from stoch cross-over to price peak in the last two cycles. Stoch crossed over again today - 30 days approx April 3 - give or take.by gingerclam5
ASX $PAR moving out of cup and handleJust getting myself adjusted to Tradingview. This setup from $PAR looks like a nice Cup and Handle formation. Posting to test out some communication features.Longby I_quacker_I8
PAR- overbought Possibility of violent reaction , this is a pivot point for me, anticipate of volatility from this point. by TungieCapital4
$PAR - PARADIGM BIOPHARMACEUTICALS - Steady riserPARADIGM BIOPHARMACEUTICALS (PAR:ASX) Has been trending nicely for a while now. More good news today with their next announcement "PARADIGM REPORTS CONSISTENT >50% PAIN REDUCTION IN KNEE OSTEOARTHRITIS PATIENTS" I like these kind of stocks in the medical space that are looking for alternative treatments to surgery. In the increasing world or obesity and ageing populations knee pain is massively increasing. How many people do you know of that have had some kind of knee surgery. Paradigm Biopharmaceuticals Limited is a biopharmaceutical company focused on repurposing the drug pentosan polysulfate sodium (PPS) for the treatment of inflammation. The Company is engaged in researching and developing therapeutic products for human use. The Company is a drug repurposing company, which seeks to find new uses for old drugs. The Company has commenced the open labelled Phase II clinical trial, investigating the role of the drug PPS in treating traumatic Bone Marrow Lesions. The Company's Rhinosul has properties consisting of both histamine stabilizing and anti-inflammatory properties. The Company focuses on repurposing PPS under ZILOSUL name, as a treatment for bone marrow edema (BME) lesions following traumatic injury. I hold. Longby zAngusUpdated 11112